Treatments of Migraine with Triptans in Individuals with Elevated Cardiovascular Risk and in Pregnant Women

CompletedOBSERVATIONAL
Enrollment

68,419

Participants

Timeline

Start Date

July 5, 2022

Primary Completion Date

November 1, 2024

Study Completion Date

November 1, 2024

Conditions
MigraineCardiovascular DiseasesPregnancy
Interventions
DRUG

Acute migraine treatment with any prescribed triptans

Sumatriptan, treximet (sumatriptan/naproxen combination), zolmitriptan, naratriptan, rizatriptan, almotriptan, eletriptan, and frovatriptan. No restriction on dose, frequency, duration, or delivery routes.

DRUG

Standard of care management of acute migraine without triptans

Any standard of care management without triptans

Trial Locations (3)

32224

Mayo Clinic Florida, Jacksonville

55905

Mayo Clinic Minnesota, Rochester

85054

Mayo Clinic Arizona, Phoenix

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Agency for Healthcare Research and Quality (AHRQ)

FED

lead

Mayo Clinic

OTHER